Abstract
Tacrolimus (FK506) is a new macrolide immunosuppressant isolated from Streptomyces tsukubaenesis that acts by a variety of different mechanisms, including inhibition of calcineurin. Although the mechanism of action of tacrolimus is similar to that of ciclosporin A, tacrolimus is 10 to 100 times more potent. Tacrolimus also has an effect on glucocorticoid receptor-mediated gene expression. The therapeutic efficacy of tacrolimus in primary immunosuppression has been evaluated in numerous clinical trials in patients receiving hepatic, renal, heart, lung, pancreas, intestinal, or bone marrow transplantation. Because tacrolimus displays a variety of different mechanisms of action and shows a synergism with corticosteroids, it is presumed that tacrolimus provides a new and useful therapeutic approach for autoimmune diseases, including myasthenia gravis.
Keywords: Anti-cholinesterase inhibitors, corticosteroids, immunosuppressant, FK-506 binding proteins (FKBP)-12, CYP enzyme
Current Drug Therapy
Title: Tacrolimus Treatment in Myasthenia Gravis
Volume: 2 Issue: 1
Author(s): Naoki Kawaguchi
Affiliation:
Keywords: Anti-cholinesterase inhibitors, corticosteroids, immunosuppressant, FK-506 binding proteins (FKBP)-12, CYP enzyme
Abstract: Tacrolimus (FK506) is a new macrolide immunosuppressant isolated from Streptomyces tsukubaenesis that acts by a variety of different mechanisms, including inhibition of calcineurin. Although the mechanism of action of tacrolimus is similar to that of ciclosporin A, tacrolimus is 10 to 100 times more potent. Tacrolimus also has an effect on glucocorticoid receptor-mediated gene expression. The therapeutic efficacy of tacrolimus in primary immunosuppression has been evaluated in numerous clinical trials in patients receiving hepatic, renal, heart, lung, pancreas, intestinal, or bone marrow transplantation. Because tacrolimus displays a variety of different mechanisms of action and shows a synergism with corticosteroids, it is presumed that tacrolimus provides a new and useful therapeutic approach for autoimmune diseases, including myasthenia gravis.
Export Options
About this article
Cite this article as:
Kawaguchi Naoki, Tacrolimus Treatment in Myasthenia Gravis, Current Drug Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488507779422437
DOI https://dx.doi.org/10.2174/157488507779422437 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Innate Immunity and Autoimmune Disease (Guest Editors: F. Susan Wong and Li Wen)]
Current Molecular Medicine Computational Studies Applied to Anti-inflammatory Drug Discovery: A Review
Current Organic Chemistry Discovery of Small Molecule Inhibitors for Prevention of Complement- Mediated Immune Hemolysis
Drug Design Reviews - Online (Discontinued) Generation and Characterization of a Functional Nanobody Against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Autoantibody-Induced Formation of Immune Complexes in Normal Human Serum
Current Pharmaceutical Design Natural and Induced Regulatory T Cells: Targets for Immunotherapy of Autoimmune Disease and Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Phospholipid/Bile Salt Based Novel Mixed Nanomicelles of Methotrexate Co-encapsulated with Sesamol: Preparation, Characterization, and Evaluation of Antiradical Effects In Vitro
Current Nanomedicine Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Hot topic: Editorial [Therapeutic Potential of Peptide Motifs - Part IV] (Jean Claude Herve)
Current Pharmaceutical Design Sjogrens Syndrome and Lymphoma Development
Current Immunology Reviews (Discontinued) Current and Future Therapeutic Targets of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design Properdin and Complement Activation: A Fresh Perspective
Current Drug Targets Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway
Central Nervous System Agents in Medicinal Chemistry Immunopathology of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery